Previous Close | 52.23 |
Open | 52.27 |
Bid | 51.49 x 1100 |
Ask | 51.63 x 4000 |
Day's Range | 50.50 - 53.14 |
52 Week Range | 42.51 - 169.76 |
Volume | |
Avg. Volume | 1,452,731 |
Market Cap | 4.003B |
Beta (5Y Monthly) | 2.01 |
PE Ratio (TTM) | 11.00 |
EPS (TTM) | 4.70 |
Earnings Date | May 09, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 121.86 |
Subscribe to Yahoo Finance Plus to view Fair Value for CRSP
Shares of Editas Medicine (NASDAQ: EDIT), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to develop therapies, saw its shares plummet 28.9% this week, according to data from S&P Global Market Intelligence. Editas' shares have steadily fallen this year, but it is hardly alone among gene-editing companies. Intellia Therapeutics is down more than 63% so far this year while CRISPR Therapeutics has seen its shares drop more than 38%.
Let's look at two stocks that boast significant upside potential, going by average price targets set by analysts on the street: Moderna (NASDAQ: MRNA) and CRISPR Therapeutics (NASDAQ: CRSP). Biotech giant Moderna fell along with the broader market in recent months. Moderna currently generates revenue from just one product: its coronavirus vaccine.
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.